John Reed, Sanofi R&D chief (Jeff Rumans)
Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Sanofi took extra time on Tuesday to offer an upbeat assessment of its top-line results for a pivotal study of a new ERT for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
